Gujarat Exclusive >

BioNTech

Pfizer, others will have to conduct clinical trials of COVID-19 vaccine in India for approval

Pfizer and BioNTech will have to conduct local clinical trials for securing emergency use authorisation for its COVID-19 vaccine, the government has said. The head of the government task force on COVID-19 vaccine, Dr. VK Paul, said that local clinical trials are a pre-condition for seeking emergency use authorisation. Notably, Pfizer and BioNTech have applied...

WHO clears Pfizer’s COVID-19 vaccine

At a time when the majority of the countries in the world are yet to approve a vaccine for COVID-19, the World Health Organisation (WHO) has given its nod to the jab developed by Pfizer and BioNTech. The development essentially means that low-income countries may soon get access to the ‘costly’ vaccine that is already...

Healthcare worker in Alaska suffers allergic reaction after taking Pfizer’s COVID-19 vaccine

In a major cause of concern over the safety and efficacy of the COVID-19 vaccine that has been granted emergency use authorisation by the authorities, an Alaskan healthcare worker who was administered Pfizer and BioNTech’s COVID-19 vaccine suffered a serious allergic reaction. The affected person is stable now after availing treatment for the allergic reaction....

UK grants approval to Pfizer’s COVID-19 vaccine, vaccination to start next week

US-based vaccine maker Pfizer and its German partner BioNTech on Wednesday announced that they have secured emergency use authorisation for their COVID-19 vaccine in the UK. The development has made the UK one of the first countries to start immunisation of its population, as early as next week, against the deadly virus that has affected...

Pfizer to seek approval for its COVID-19 vaccine, claims it is 95% effective

Pfizer and BioNTech on Wednesday announced that after conducting the final efficacy analysis in their ongoing Phase 3 study, their COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% in participants without prior SARS-CoV-2 infection and also in participants with and...

Pfizer, BioNTech’s COVID-19 vaccine found 90% effective in phase 3 trial

Pfizer and BioNTech on Monday announced that their mRNA-based vaccine candidate, BNT162b2, has been found to be effective against COVID-19 in participants without prior evidence of coronavirus infection. The results are based on the first interim efficacy analysis conducted on November 8 by an external, independent Data Monitoring Committee (DMC) from the phase 3 clinical...

Germany approves human trials of potential COVID-19 vaccine

Germany has given a green signal to human clinical trials of a potential coronavirus vaccine, according to a report on Independent. According to the report, during the first stage, the trial will be conducted on 200 healthy participants between the age of 18 and 55, who will receive several variants of the vaccine, developed by...